ArticleScientific reports2026
Long noncoding RNA FOXP1-DT modulates regulatory T cells in Graves' disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Regulatory T cells (Tregs) are key contributors to maintaining immune system stability, and their impairment has been linked to the pathogenesis of Graves' disease (GD). However, the precise molecular mechanisms driving Treg dysregulation in GD remain poorly understood. Our previous study identified a dysregulated long noncoding RNA, FOXP1-DT (forkhead box P1 divergent transcript), which might be related to Treg cells. This study aimed to investigate the role of FOXP1-DT in Tregs from individuals with GD. Fifteen patients diagnosed with GD and fifteen age- and sex-matched healthy controls were recruited. Our findings demonstrated that FOXP1-DT expression was markedly decreased in the peripheral blood mononuclear cells of GD patients and exhibited an inverse correlation with the concentration of thyroid-stimulating hormone receptor antibody. FOXP1-DT is mainly located in the nucleus and adjacent to the FOXP1 gene in the genome, a key transcription factor for Treg homeostasis. FOXP1 expression was also significantly reduced in GD patients and correlated positively with FOXP1-DT expression and Treg cell levels. Moreover, silencing FOXP1-DT reduced FOXP1 expression and Treg cell proportion, consistent with the clinical observation of a positive link between decreased FOXP1-DT expression and lower Treg frequency in GD patients. ROC curve analysis showed the potential biomarker value of FOXP1-DT in GD. These findings indicate that downregulated FOXP1-DT may be involved in the process of GD by regulating FOXP1-mediated Treg dyshomeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.